• Hongqiang An, Bing Li, Jifeng Zhao, Zhijian Ao, Xiaohui Zhong, Pengfei Zhu, and Jianlin Wu.
• Xintai Affiliated Hospital of Shandong First Medical University.
• Medicine (Baltimore). 2020 Dec 18; 99 (51): e23826.

BackgroundSciatica is one of the common clinical diseases. Studies have proved the efficacy of Chinese patent medicine (CPM) in the treatment of sciatica, so far, there has not been a complete systematic review of its effectiveness and safety, and the comparative efficacy and safety of CPM have not been ranked. Therefore, it is necessary to evaluate the efficacy and safety of these CPM by means of systematic review and network meta-analysis (NMA), and to compare them in order.MethodsWe will search PubMed, Cochrane Library, EMbase, Web of Science, CNKI, Wanfang, VIP, CBM and other databases for RCTs of CPM in the treatment of sciatica, (database established until December 30, 2020). In addition, we will manually search the "Pharmaceutical Information", "National Essential Drug List", "Chinese Pharmacopoeia", etc. to inquire about drug instructions, and screen the market circulation and clinically commonly used CPM. We will use RevMan software, gemtc package, GeMTC software for statistical analysis, and draw the surface under cumulative ranking area (SUCRA) to predict the order of curative effect of treatment measures.ResultsOur study will compare and evaluate the effectiveness of CPM in the treatment of sciatica, and rank different CPM. The outcome indicators will include clinical efficacy, pain degree, lumbar spine function and adverse events.ConclusionOur research will provide support for clinical practice.Inplasy Registration NumberINPLASY2020110073.Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

20 keywords...

hide…